Sanofi signs agreement to acquire Inhibrx for $1.7bn
Sanofi has signed a definitive agreement for the acquisition of all outstanding shares of Inhibrx for an equity value of $1.7bn.
Sanofi has signed a definitive agreement for the acquisition of all outstanding shares of Inhibrx for an equity value of $1.7bn.
What's Your Reaction?
